Analysis: Bitcoin long-term holders' positions rise near historical highs, breaking the downtrend of the past two and a half years
ChainCatcher news, according to CoinDesk, the holdings of long-term Bitcoin holders continue to rise and have now reached approximately 16.3 million BTC, close to the historical highest level. The downtrend of nearly two and a half years has been broken.
Long-term Bitcoin holders are typically investors who hold their coins for more than 155 days. Since Bitcoin reached its historic high of about $126,000 in October 2025, their holdings have increased from approximately 14.12 million BTC to the current level, with a solo increase of around 200 thousand BTC in the past month.
Historically, this indicator only approached higher levels (about 16.4 million BTC) in January 2024, right before the launch of the US Bitcoin spot ETF. Afterwards, as the market rallied, long-term holders reduced their positions by a cumulative total of about 2 million BTC over several months.
During typical bear markets or price correction phases, long-term holders typically re-enter accumulation cycles. This means that during periods when Bitcoin prices are under pressure, “smart money” is flowing back into the market.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
Crypto prices
More
